ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag drug development biotech tuberculosis cancer

Take Two of These
Bob Grant | Jun 22, 2011 | 6 min read
Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
The Little Cell That Could
Megan Scudellari | Jul 1, 2012 | 7 min read
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
High-Priced Biotech Drugs: Are They Worth It?
Susan Warner(swarner@the-scientist.com) | Dec 5, 2004 | 6 min read
4,000 for a course of treatment.
Pharmaceutical And Biotech Firms Taking On Drug-Resistant Microbes
Kathryn Brown | Jun 9, 1996 | 9 min read
Drug-Resistant Microbes As pesky pathogens continue to evolve, new technologies to combat them are emerging, spelling job opportunities for molecular biologists and chemists. OBSTINATE MICROBES: Margaret Rennels cites strains of pneumococcus resistence to two major drugs. At drug and biotech companies across the United States, scientists have set their sights on a most elusive target: drug-resistant microbes. Working in pharmaceutical- biotechnology partnerships, researchers are trying every
Biotech Faces Evolving Patent System
Douglas Steinberg | Mar 5, 2000 | 8 min read
Like medieval alchemists, modern biologists apply intricate, esoteric protocols to lowly matter, such as bacteria and rodents. Unlike alchemists, biologists successfully transmute these creatures into gold--disease-fighting pharmaceuticals and profits accruing from them. An indispensable ingredient in this dross-to-drug process is patent protection, which preserves monopoly and attracts investment. Unfortunately, the patent system isn't as ideal a catalyst as the chimerical philosopher's stone s
When Biotechs get Makeovers
Alison McCook(amccook@the-scientist.com) | Oct 9, 2005 | 9 min read
It was the beginning of 2002, and employees of Renovis, a biopharmaceutical company based in San Francisco had many reasons to celebrate.
A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Amos Zeeberg, Undark | Feb 27, 2023 | 8 min read
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
Artist’s rendering of various orange and pink colored bacteria
Q&A: What if Immune Cells Don’t Actually Detect Viruses and Bacteria?
Dan Robitzski | Feb 3, 2023 | 10+ min read
The Scientist spoke with Jonathan Kagan about his idea that immune cells respond to “errors” made by unsuccessful pathogens, not the pathogens themselves.

Run a Search

ADVERTISEMENT